Get notified when HURA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (unchanged) — Substantial doubt about ability to continue as going concern remains disclosed in both filings.
- Delisting (new) — Received Nasdaq delisting notice January 2026 for bid price below $1; regained compliance February 2026.
TuHURA closes Kineta acquisition, starts Phase 3 trial, but cash dwindles to $3.6M
Filed March 31, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 31, 2025 · ~1 min read
Key Changes
-
high
Completed Kineta acquisition in June 2025 for ~4M shares, adding TBS-2025 VISTA antibody targeting AML; planning Phase 1b/2 trial in relapsed/refractory mutant NPM1 AML for H2 2026.
Business: Kineta acquisition verify on EDGAR → -
high
Initiated Phase 3 trial for IFx-2.0 in Merkel cell carcinoma in June 2025 after FDA lifted partial clinical hold; enrollment now expected to take 18-24 months (vs. prior 12-month estimate).
Business: Phase 3 trial verify on EDGAR → -
high
Cash fell to $3.6M (Dec 2025) from $12.7M (Dec 2024) despite raising $28M gross in two equity offerings; runway extends only to Q3 2026, signaling near-term financing pressure.
MD&A: Cash position verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.
Partner
Trade HURA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify